IBC
19.9.2018 12:05:11 CEST | Business Wire | Press release
IBC2018 has closed its doors for this year and has delivered another great event with visitor figures of 55,884. As well as providing a host of new initiatives this year, the exhibition grew by 667m2 and conference delegates were up by 14% year on year. One of the most important growth figures lies in the diversity of its content with a targeted effort increasing women speakers at the conference up from 14% to 37%.
The IBC International Honour for Excellence saw its first-ever woman recipient this year, too. Joan Ganz Cooney was the co-creator of the global phenomenon that is Sesame Street , 50 years ago and her trophy was collected on her behalf by one of the street’s longest residents, Ernie.
The IBC App has provided real networking opportunities, with more than 91,000 interactions on the matchmaking platform. In addition, IBC trended number one on Twitter in the Netherlands on several days of the convention, with 185 million potential impressions and over 250,000 video views. Engagement with IBC has also increased on a year-round basis with IBC365 – the site now has over 55,000 subscribers averaging 49,000 active users per month.
Michael Crimp, IBC’s CEO, comments; “The show is about engagement, engagement, engagement. The stats are up in almost all areas and re-bookings are ahead of last year. IBC is much more than a trade show, we have developed a basket of data-driven statistics including sales leads generated on stands, conference attendance and IBC365 views and this sharing of information is pivotal to the longevity of IBC’s success and sits at the core of the organisation.”
“All of the initiatives this year have been aimed at bringing together the best minds, the original thinkers, to network and share their knowledge. As all communication becomes video and audio, IBC continues to be the place to debate the future of media, technology and entertainment,” adds Crimp.
Guiding the renewed focus this year was a new content steering group, drawn from across the industry, and chaired by Keith Underwood, Chief Operating Officer at Channel 4 in the UK.
IBC head of content Jaisica Lapsiwala, said, “This year, we have worked closely with the industry to create a programme that is not only reflective of the changes in the ecosystem, but which also paves a path forward for our industry. This has resulted in an engaging and diverse 2018 edition of IBC. An example of this was our Global Gamechangers day which brought creative, technology and business chiefs such as Zahra Rasool from Al Jazeera, Peter Salmon from Endemol and Lindsay Pattison from WPP to the stage. Threaded through the programme were the cutting-edge technologies transforming the industry. Blockchain is a great example, with a keynote from Kim Jackson of Singular DTV and papers from people who are already implementing it, like Éric Minoli of Groupe Média TFO.”
Alongside the conference, IBC hosted three invitation-only executive forums. The Leaders’ Forum looked to the future, considering what the new ecosystem could be following consolidation, acquisition and collaboration. The Cyber Security Forum considered not just the threats but how to respond to them. New to the programme this year was the Telco and Media Innovation Forum, a vital point of debate as the boundaries between media and communication blur.
Once again, IBC was the venue for an examination of the intersection of craft and technology in The Big Screen. Sessions included an in-depth look at the effects in Game of Thrones and Pixar’s Dominic Glynn talking about the animation marvel that is The Incredibles 2 – and how things have changed in the 14 years since the original movie.
The Future Zone is always a busy part of IBC, with presentations from researchers and academic bodies developing the ideas which may become the hit products five years from now. This year saw the addition of a theatre stage, presented by one of IBC’s owners, IABM, with a rolling programme of presentations discussing the ideas in more detail.
As well as the IBC Big Screen, the IABM Future Trends Theatre and the Content Everywhere Hub, staged presentations and enlarged on-stand meeting areas are becoming an increasingly common feature of exhibition stands throughout the show. “As the industry has moved on from big boxes handling discrete functions towards a software-based world that looks across the content supply chain, so the way vendors present themselves and interact with visitors at IBC has changed,” said Roger Thornton, chair of the IBC exhibition committee.
“Today, it’s all about collaboration to deliver solutions that give broadcast and media companies the agility and flexibility they need to keep ahead in this rapidly transforming media landscape. That’s why we’re seeing more and more companies using big-picture theatre presentations on their stands and providing large meeting areas where the conversations that kick off the collaboration get started.”
IBC2019 starts with the first day of conference sessions on Thursday 12 September, running until the exhibition closes on Tuesday 17 September.
-ENDS-
Notes to Editors:
About IBC
IBC is the world’s most influential media,
entertainment and technology show, attracting 55,000+ attendees from
more than 170 countries and combining a highly respected and
peer-reviewed conference with an exhibition that showcases 1,700+
leading industry suppliers of state-of-the-art technology. In addition
to the world-class exhibition and conference, IBC also encompasses the
IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
IBC2019 Dates
| Conference: | 12 - 16 September 2019 | ||||
| Exhibition: | 13 - 17 September 2019 |
For more information about IBC2019 visit: show.ibc.org/
View source version on businesswire.com: https://www.businesswire.com/news/home/20180919005306/en/
Contact:
Bubble Agency Louise Wells E: louisew@bubbleagency.com T: +44 7718 985 252
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
